CORDIS
EU research results

CORDIS

English EN

Efficiently Networking European Neurodegeneration Research

Project information

Grant agreement ID: 821513

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    28 February 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 2 353 125

  • EU contribution

    € 1 199 125

Coordinated by:

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

Objective

The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.
This will be achieved through the following specific objectives: 1) creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI ND projects; 2) designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders; 3) supporting the management of the programme (timelines, dependencies, synergies and key results across projects); 4) proactively detecting needs, opportunities and transferable best practices of projects and to connect them; 5) providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues; 6) promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field; and 7) preparing and securing the long-term sustainability of NEURONET itself.
Achievement of these objectives will necessarily rely on buy-in from existing and future projects in the IMI ND portfolio, and effective connections with other programmes and initiatives in Europe and beyond, including stakeholder representation.
For this, the Consortium has been constituted by very active partners in a variety of IMI ND projects and related initiatives with specialists in areas like complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.

Coordinator

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Address

Calle Velazquez 94 Planta 1
28006 Madrid

Spain

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 588 250

Participants (9)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

United Kingdom

EU Contribution

€ 303 250

ALZHEIMER EUROPE

Luxembourg

EU Contribution

€ 307 625

JANSSEN PHARMACEUTICA NV

Belgium

Eli Lilly and Company Limited

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

TAKEDA DEVELOPMENT CENTRE EUROPE LTD

United Kingdom

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG

United Kingdom

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

Switzerland

Project information

Grant agreement ID: 821513

Status

Ongoing project

  • Start date

    1 March 2019

  • End date

    28 February 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 2 353 125

  • EU contribution

    € 1 199 125

Coordinated by:

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain